755039-73-7

Basic information

• Product Name: D-Alanine, N-(1-methylethyl)-, methyl ester (9CI)
• Synonyms: D-Alanine, N-(1-methylethyl)-, methyl ester (9CI)
• CAS NO: 755039-73-7
• Molecular Formula: C7H15NO2
• Molecular Weight: 145.1995
• Product Categories: GLYCINESCAFFOLD
• Mol File: 755039-73-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: D-Alanine, N-(1-methylethyl)-, methyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: D-Alanine, N-(1-methylethyl)-, methyl ester (9CI)(755039-73-7)
• EPA Substance Registry System: D-Alanine, N-(1-methylethyl)-, methyl ester (9CI)(755039-73-7)

Safety Data

• Hazardous Substances Data: 755039-73-7(Hazardous Substances Data)

Usage

General Description

D-Alanine, N-(1-methylethyl)-, methyl ester (9CI) is a chemical compound with the molecular formula C7H15NO2. It is the methyl ester of the amino acid D-alanine, and is commonly used in the synthesis of peptides and pharmaceuticals. D-Alanine, N-(1-methylethyl)-, methyl ester (9CI) is a colorless liquid that is soluble in organic solvents and has a faint odor. It is commonly used as a building block in organic chemistry reactions and is considered to be a versatile intermediate in the production of various compounds. Overall, D-Alanine, N-(1-methylethyl)-, methyl ester (9CI) has a variety of applications in the chemical and pharmaceutical industries.

Upstream product

• 7625-53-8 D-alanine methyl ester 
• 67-64-1 acetone 
• 14316-06-4 D-alanine methyl ester hydrochloride 

Relevant articles and documents

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC50 = 2579 nM, PLK1 IC50 = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to new dihydropteridinones of general formula (I) wherein the groups L and R1- R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropterid